PURPOSE: The purpose of this review is to provide an update on the epidemiology and current antibiotic-resistant threats in ophthalmology.
Introduction
O cular infectious diseases (blepharitis, c o n j u n c t i v i t i s , k e r a t i t i s , a n d endophthalmitis) are responsible for a high degree of visual morbidity and blindness worldwide. Greater than 70% of all ocular infections are associated with Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Moraxella species, Pseudomonas aeruginosa, Candida albicans, Aspergillus species, and Fusarium species. The frequency and pathology may fluctuate depending on age, gender, climate, healthcare access, and culturing frequency.
Despite the higher drug concentrations obtained in ocular tissues when using topical antibiotics, there are increasing reports of clinical failure and/or less than optimal outcomes with empirical treatment with each new fluoroquinolone generation. [1, 2] Miller: Update on antimicrobial resistance and ocular infections Similar to nonocular isolates, there is an increasing threat to patient safety and poorer outcomes in the management of antibiotic-resistant or nonsusceptible isolates.
The true prevalence of antibiotic resistance and associated clinical failure, however, is unknown. The current standard of care is to treat first and culture later (if ever). There is no national or international clearing house to monitor antimicrobial resistance among common and uncommon bacterial and fungal ocular pathogens.
Regional and local trends in pathogen frequency and antibiotic resistance vary by time, geographic region, and patient population sampled. The Center for Disease Control and Prevention lists monitoring and tracking antibiotic resistance as one of the four cornerstones to reduce and protect against emerging antibiotic threats. [3] Current surveillance and tracking programs for ocular pathogens need to be expanded and coordinated.
The purpose of this review is to provide an update on the epidemiology in ocular pathogen trends and current antibiotic-resistant threats in ophthalmology.
Methods
The Miami Microbiology database was searched and data on trends in organism frequency, diversity, and antibiotic profiles extracted and reviewed for isolates collected between January 2005 and December 2015 with emphasis on the past 5 years (2011) (2012) (2013) (2014) (2015) . The study was performed with the approval of the University of Miami Institutional Review Board.
Isolates were identified using the Vitek 2 Compact System (BioMerieux, Durham, NC, USA) and a combination of rapid kits and standard microbiology protocols. Susceptibility data were compiled using the Vitek 2 computerized susceptibility database and E-test (BioMerieux, Durham, NC, USA).
Organism frequency and susceptibility profiles from our institute were compared with the Antibiotic Resistance Monitoring in Ocular Microorganism (ARMOR) 5-year study and/or comparable and appropriate national and international studies involving results of isolates collected and reported in literature between 2011 and 2015.
Statistics
Chi-square was used to evaluate differences in proportions. Significance, P < 0.05, 95 CI was determined using online software Med Calc, Belgium https://www. medcalc.org/and/or Microsoft 2013 Excel software.
Results
A total of 10,589 isolates were recovered and reviewed over the 11-year study period. There was a significant (P < 0.0001, 95 CI [1.8000-4.8083 Trends in organism group frequency over time are highlighted in Figure 1 . Bacterial species were the predominant organism group for all time periods and ranged from 82% to 87.1%. There was a significant difference in bacterial recovery rates for period I (85.3%, n = 5066, 2005-2010) versus period II (87.1%, n = 4049, 2011-2015), (P < 0.0136, 95 CI 0.3583 − 3.2305).
A significant increase and crossover of Gram-positive bacteria versus Gram-negative bacteria occurred during the most recent 5 years. Compared to period I (n = 2227, 37.5%), the proportion of Gram-positive isolates increased by 8.4% (P = 0.0001).
This shift was paralleled by a decrease in Gram-negatives by 7.4% (44.6%, n = 2649 vs. 37.5%, n = 1743) (P < 0.001; 95 CI 31.3961-34.000). There was no significant change in the recovery of Mycobacteria species (3.2%, n = 190 vs. 3.7, n = 172) between the two periods (P = 0.1600, 95 CI − 0.2104-1.2263).
Among the nonbacterial isolates, significant declines in recovery of molds (9%, n = 535 vs. 7.6%, n = 353) (P = 0.0099, 95 CI 0.3268-2.4622) and Acanthamoeba species (2.2%, n = 137 vs 1%, n = 46) (P < 0.0001, 95 CI 0.7135-1.6850) were documented between period I and period II. Recovery of yeast isolates increased by 1.3% (3.5%, n = 208 vs. 4.8%, n = 223; P = 0.0008). Table 1 outlines the trends in recovery rates between the two periods for the most common ocular bacteria pathogens. There were marginal increases in three of the four Gram-positive pathogens and ranged from 1.7% for the Streptococcus viridans group to 4.6% for S. aureus. The net increase for Gram-positive isolates was 8.8%. Significance was only observed for S. aureus. Significant decreases for two of the three Gram-negatives on the list were observed and ranged from 1.3% for Haemophilus influenzae to 2.2% for P. aeruginosa. The net decline for Gram-negative pathogens was 2.8%.
Abundance and diversity of the top five isolates differed by ocular sources and/or patient population sampled [ Table 2 ]. Gram-positive isolates remain the most frequent isolates overall, but frequency was dependent on ocular source or patient population sampled.
Recovery rates by source for Gram-positive pathogens in descending order were endophthalmitis (90.9%, n = 180), conjunctivitis (62.8%, n = 402), and keratitis (26.4%, n = 395). Recovery rates for Gram-negatives isolates in descending order included keratitis (42.7%), conjunctivitis (37.3%), and endophthalmitis (11.0%). The ratio of Gram-positive to Gram-negative among the top ten most common ocular pathogens was 1.9:1. S. aureus remains the most common bacterial pathogen overall and ranged from 7.6% for endophthalmitis to 35.5% for conjunctivitis. P. aeruginosa was the most frequent pathogen recovered from patients' samples submitted to rule out keratitis. Coagulase-negative staphylococci (CoNS; n = 71, 35.8%) remain the top patients recovered from patients with endophthalmitis. Table 3 compares trends in conjunctiva isolates from three regions; Miami, FL, USA (2011-2015, n = 786), Pittsburg, PA, USA (1993-2011, n = 1320), [4] and Lagos, Nigeria (2010, n = 155). [5] Spectrum and diversity were distinct for all other locations. Greater than two-thirds of the recovered isolates were Gram-positive for samples evaluated from populations in Pittsburg and Lagos. S. aureus was the most frequent pathogens in all three locations. Among the remaining isolates, only Moraxella species was common to all three groups. Gram-positive isolates were the dominant conjunctival pathogens, and recovery rates ranged from 57.1% to 72%. [6] and Hospital Universiti Sain Malaysia (HUSM, Malaysia, Malaysia, n = 1211.) [7] Profiles were distinct for each location. Greater than 85% of isolates recovered from keratitis at KKESH were Gram-positive versus 42.6% and 40.5% for HUSM and Miami, respectively. S. aureus isolates ranged from 7.8% (HUSM) to 20.6% for Miami. Methicillin resistance was significantly higher (16.8%, P = 0.0001, 95 CI 8.3935-24.9972) among S. aureus rates from Miami versus KKESH (36.2%, n = 227 vs. 19. 4%, n = 237). The reported methicillin-resistant S. aureus (MRSA) rate for HUSM was the lowest at 7% (n = 94).
The greatest contrast was observed for recovery rates for CoNS. These were the most frequent isolates recovered from keratitis at KKESH with a rate of 47.2%. The recovery rate for coagulase-negative isolates in Miami was 9-fold less at 5.2%. No CoNS were detected among the isolates from Malaysia.
Gram-negative bacteria were the predominant organism group recovered in two of the three studies and ranged from 12.5% (KKESH) to 57.4% for HUSM. Recovery rates for Miami were 2.4-fold greater than those for KKESH. Malaysia had the highest Gram-negative rates, 1.1-fold higher than the BPEI and 2.7-fold greater than the rate for KKESH. P. aeruginosa was the top pathogen for only one of these (Miami, 35.7%) but was the second most frequent pathogen in keratitis isolates from Malaysia at 16.0%. P. aeruginosa was recovered from the cornea at least 3.3 times more frequent than KKESH and 2.1 times more frequent than the recovery rate for HUSM.
Eighty-five percent of microorganisms recovered from vitreous samples during this period were Gram-positive, with S. epidermidis being the most frequent at 29.7%. Gram-negative bacteria were not among the top five pathogens for patients with endophthalmitis for this period.
Antibiogram Table 5 provides a cumulative Antibiogram Report for Ocular Isolates collected for the most recent 5 years (2011) (2012) (2013) (2014) (2015) . It follows the recommendations of the Clinical Laboratory Standard Institute (M3-A2, CLSI document) [8] for preparation. [9, 10] 
Fluoroquinolones
O v e r a l l , e m p i r i c a l t h e r a p y w i t h a fluoroquinolones (ciprofloxacin, 76.6%, n = 2338) and/or levofloxacin (77.1%, n = 2447) provided < 80% coverage for the top three (S. aureus, CoNS, and P. aeruginosa) pathogens in our study. Individual susceptibility was species specific.
Gram-negatives
Less than 10% resistance was reported for the most common Gram-negative isolates for ciprofloxacin and/or levofloxacin during the most recent 5-year test period. Percent susceptible 
Gram-positives
Overall, in vitro susceptibilities for the fluoroquinolones were <90% for both methicillin-susceptible and methicillin-resistant S. aureus and S. epidermidis.
No significant difference in MSSA (n = 560) versus MRSA (n = 407) susceptibilities for moxifloxacin versus ciprofloxacin was documented.
Methicillin resistance was >40% for both S. aureus and S. epidermidis and ranged from 36.2% for keratitis (n = 224) to 43.8% for dacryocystitis (n = 73). Multidrug resistance was more likely to occur in MRSA and MRSE isolates [ Table 6 ]. The highest level of nonsusceptbility to the fluoroquinolones among methicillin-susceptible isolates was observed for S. epidermidis (27%).
Levofloxacin remained above 90% susceptible for both S. pneumoniae (100%) and S. viridans (91%). While the Percentage susceptible interpretations based on Clinical Laboratory Standards Institute breakpoints. [9, 10] Data in this document use PD/PK data for individual bug/ drug combinations in serum and tissue to generate breakpoints. Duplicates were excluded, only isolates and/or species numbering 30 or more were included in the antibiogram. Statistical validity or estimates of percent susceptibility for organisms for which there are fewer than 30 isolates is limited and could lead to inappropriate selection of empirical therapy MRSA=42%
Methicillin resistance was determined using the cefoxitin screen ( 
Aminoglycosides
Nonsusceptibility among the aminoglycosides (amikacin, gentamicin, and tobramycin) was <20% for all Gram-negative isolates tested during 2011-2015. Gentamicin susceptibility was <90% for all staphylococci excepted for MRSE which declined to < 80%. No significant differences in gentamicin susceptibility rates for S. aureus (94.5%, n = 1038 vs. 95%, n = 967) or S. epidermidis (82.5%, n = 165 vs. 86%, n = 287) were observed between periods. Tobramycin is not recommended for in vitro testing of staphylococci.
Neither gentamicin nor tobramycin is recommended for in vitro testing of Haemophilus species and/or streptococcal species.
Susceptibilities for amikacin, gentamicin, and tobramycin were ≥90% for all Gram-negatives isolates tested. There was a significant difference in the susceptibility for gentamicin and tobramycin for both S. marcescens and P. aeruginosa. Higher susceptibility rates for gentamicin (99%) versus tobramycin (92 %), P = 0.0024, 95 CI 2.2424-12.3802 to was documented for S. marcescens, while the opposite trend was observed for P. aeruginosa for both periods (I -97% vs. 99%, P = 0.0019, 95 CI 0.6847-−3.4035; II -96% vs. 100%, P < 0.0001, 95 CI = 2.4588 to 5.9009). Ceftazidime nonsusceptibility ranged from 1% to 3% with the highest rate of extended spectrum beta-lactamases being documented for Klebsiella species. Susceptibility for the staphylococci was < 60%.
Ampicillin/penicillins
There was a high rate of resistance to penicillin among the streptococci. Penicillin nonsusceptible S. pneumoniae rate using nonmeningitis interpretation was 47%. Penicillin susceptibility for the S. viridans group was 81%. Ampicillin susceptibility for the Haemophilus species was <80% for isolates recovered during 2011-2015.
Carbapenem (imipenem/meropenem) nonsusceptibility among the Enterobacteriaceae was rare. Rates for P. aeruginosa during the last 5 years was 3% (n = 461/473).
Fluoroquinolone monotherapy provided less than 80% coverage (levofloxacin -77.1%) for gram positive isolates. Combination therapy with a fluoroquinolone and vancomycin coverage was 99.1% (vancomycin and levofloxacin) or (98.9%) vancomycin and ciprofloxacin. Vancomycin plus gentamicin coverage was 98.3%.
Our corneal isolates differed from those recovered from KKESH. No moxifloxacin resistance was documented for KKESH S. aureus isolates (n = 237, 100%). The rate for Miami corneal S. aureus isolates was 55% (n = 225). This 45% difference was significant (P < 0.0001, 95 CI 38.2037-51.7519). No significant differences were observed for fluoroquinolones susceptibility among conjunctival P. aeruginosa isolates versus isolates in the ARMOR study. Significant differences and higher susceptibilities were observed for Miami P. aeruginosa corneal isolates for both ciprofloxacin (6.4%, P < 0.0001, 95 CI 3.1577-10.2405) and levofloxacin (7.4%, P < 0.00001, 95 CI 4.3335-11.1585). Eighty-one percent of the indefinable (n = 216) P. aeruginosa isolates from the ARMOR study were from the cornea. [11] BPEI data for 2011-2015 mirrored these results.
Antibiotic Resistance Monitoring in Ocular Microorganism Study
P. aeruginosa isolates from KKESH were significantly more resistant to ciprofloxacin (95%, n = 123 vs. 99% n = 396, P = 0.0051, 95 CI 0.5203-9.5239) and ceftazidime (94.3%, n = 123 vs. 99%, n = 393, P = 0.0016 95%) than isolates from Miami during a similar testing period.
Aminoglycoside susceptibility (gentamicin-Miami, tobramycin-ARMOR) profiles were >90% for all MSSA and MRSA isolates from Miami with significantly higher rates for both groups compared to ARMOR. MSSA, (98.5% vs. 95.6%, P = 0.0055, 95 CI 0.6995-4.5573) and MRSA (90.9% vs. 55.8%), P < 0.0001. Results paralleled results for the current period.
There was a 32.1% difference in aminoglycoside susceptibility for isolates from the conjunctiva (87.8% vs. 55.8%, P < 0.0001, 95 CI 23.2676-39.1837) versus those collected ARMOR study. Susceptibility profiles for the staphylococci recovered from the cornea were higher and differed by 32.2%, P < 0.0001 95 CI 23.0648-39.7981.
Tobramycin susceptibilities were distinct and significantly higher for isolates from Miami versus those in the ARMOR study. The difference was 2.9% (P < 0. No significant differences were documented for P. aeruginosa isolates to ciprofloxacin among isolates corneal from KKESH (n = 123, 95%) versus isolates from the ARMOR study (n = 389, 92.3%).
Discussion
Both culture-independent and culture-dependent methods identify a diversity of microorganisms at the ocular surface in health and disease. [12] [13] [14] [15] The top pathogens remain S. aureus, S. pneumoniae, CoNS, H. influenzae, P. aeruginosa, Chlamydia trachomatis, C. albicans, Fusarium species, and Aspergillus species. In general, now including Miami, Gram-positive bacteria remain the most common microbial agents recovered from ocular infections worldwide. [1, 16] A 2011 report by Iwalokun et al. identified S. aureus as the most common bacteria pathogen among 155 isolates recovered from 83 conjunctiva samples collected during an 8-month period (February-September 2010). Gram-positive isolates constituted 72% of the isolates. P. aeruginosa was the most frequent Gram-negative pathogen (n = 15, 9.7%). [5] Worldwide, the etiology and frequency in microbial keratitis is greatly influenced by climate and patient population. Bacterial pathogens are the most common in industrialized countries, while fungi and parasites are more frequent in developing nations. [17] [18] [19] Staphylococci species and S. pneumoniae are among the leading bacteria cause of microbial keratitis. Gram-negative isolates, predominately P. aeruginosa, may be increasing and have been reported more frequently from Miami, East Kent, and Saudi Arabia. [20, 21] Reports from the Middle East and Africa are scarce. A recent report by Burton et al. identified microbial keratitis as a significant burden of disease and cause of blindness in East Africa. [19] Prevalence estimates range from 113/100,000 to 789/100,000. Filamentous fungi were the most common pathogens, compounded by underlying HIV diseases. Gebremariam in a small series of 24 isolates documented P. aeruginosa (41.7%) as the most common pathogen.
Al-Dhaheri et al. documented staphylococci (91.4%) as the leading cause in a recent series documenting trends in keratitis from KKESH from 2011 to 2014. P. aeruginosa was recovered in <10% of isolates. The diversity and spectrum of pathogens might reflect the dry climate and the small number of contact lens wearers. [6] Data from Malaysia documented S. aureus as the predominant pathogen; [17] however, recovery rate for Gram-negatives was 57.4% versus 46.6% for Gram-positive isolates. P. aeruginosa was the top Gram-negative isolate at 16.0%. No CoNS were recovered in this series. [7] Kowalski (2013) identified S. aureus and S. pneumoniae as the top pathogens recovered from samples submitted to the Campbell laboratory over a 19-year period. [4] Gram-negative isolates were recovered in less than a third of the isolates (30%). This was significantly different than current and historical trends from Miami and might demonstrate the influence of geography and climate on pathogen recovery. 
Endophthalmitis
Gram-positive isolates, predominantly CoNS, remain the most common isolates recovered from endophthalmitis. [22] [23] [24] The spectrum and diversity is expanding and varies dependent on endophthalmitis category.
Susceptibility tests
Comparing susceptibility results across cities and nations are difficult. Data are hindered by testing standards, interpretation, methodology, and expertise. We limited our in vitro comparison to the ARMOR cumulative study (2009) (2010) (2011) (2012) (2013) and data from reports with similar methodology (MIC breakpoints).
Fluoroquinolones
The fluoroquinolones remain the most frequently dispensed class of topical antibiotics in the treatment ocular infections. [1, 2, 25] Susceptibility is driven by availability and frequency of use. In areas such as the United States, Brasil, and India, where use is high, emerging and nonsusceptible rates are as high as 70% for the staphylococci (both methicillin sensitive and methicillin resistant) and ranged from 1% to 29% for P. aeruginosa and the Enterobacteriaceae. [26] [27] [28] In regions where use is limited and/or minimal, Australia, Africa, and the Middle East, rates are as low as 1%. [6, 19, 29] Cross resistance among the fluoroquinolones are high, but reported lower minimal inhibitory concentrations are observed for besifloxacin. [26, 30, 31] In a study by Miller et al., besifloxacin MICs was 2-4 times lower than ciprofloxacin, levofloxacin, and moxifloxacin for fluoroquinolone susceptible and or resistant staphylococcal ocular isolates. [32] Similar results are observed for both S. aureus and CoNS in the cumulative ARMOR surveillance data and the original ARMOR study.
Differences in the current Miami study and the ARMOR 5-year report was "bug and drug" specific. This study confirmed the continued rise in nonsusceptibility among the staphylococci (both methicillin susceptible and resistant) among the fluoroquinolones and the associated multidrug coresistance. Emerging fluoroquinolone resistance among the alpha hemolytic streptococci and ceftazidime resistance among P. aeruginosa is worrisome.
In a recent surveillance study involving seven European countries (France, Germany, Italy, Poland, Slovak Republic, Spain, and the UK, January-August 2011), susceptibility results for S. aureus ocular isolates (n = 252) ranged from 0% to 31.1% for moxifloxacin and 5.3%-31.1% for ciprofloxacin. The average rate was 14.7% for ciprofloxacin and 12.7% for moxifloxacin.
Among the countries who submitted 30 or more isolates, the lowest fluoroquinolone resistant or nonsusceptible rates were documented for France (n = 53, 7.5% for ciprofloxacin and moxifloxacin) and the UK (n = 46, 8.7% for ciprofloxacin and 6.5% for moxifloxacin). Highest rates were documented in isolates collected from Germany (n = 45), with a 31.1% for both drugs. [33] Methicillin resistance was only 9.1% for this group with the highest rates reported for Germany at 20.0%. These rates were significantly lower than those reported in the current study and/or those highlighted in the ARMOR study.
Methicillin resistance among coagulase-negative isolates (n = 313) averaged 55%. The highest rates were observed in Spain at 75% (n = 32) and lowest in the UK at 48% (n = 50). Fluoroquinolone resistance ranged from 6.0% to 48.5%.
A total of 70, S. pneumoniae, 64 H. influenzae, and 39 P. aeruginosa isolates were submitted during the 20 months test period. All isolates were 100% susceptible to moxifloxacin and/or ciprofloxacin, except P. aeruginosa. Nonsusceptibility to ciprofloxacin among P. aeruginosa in the European study was 10.8%. This rate was 5-fold higher than the 2% rate reported in this study and 3-fold higher than for isolates in the ARMOR study.
Results for S. pneumoniae and H. influenzae were in line with the results for the current and ARMOR studies. Comparative result should be viewed, however, with caution due to the low numbers in the European study.
Aminoglycosides
Worldwide, susceptibility to the aminoglycosides is also impacted by use, availability, and disease profile. In areas where fluoroquinolone monotherapy has supplanted traditional use of the aminoglycosides with a cefazolin for dual therapy, in vitro susceptibilities rates are higher. [34] Sanfilippo et al. documented differences in nonsusceptibility for gentamicin and tobramycin among S. aureus, CoNS, and P. aeruginosa in a recent surveillance study from Europe. [33] Nonsusceptibility rates for gentamicin among the staphylococci ranged from 2.0% to 28.4%, with highest rates for coagulase-negative isolates. In contrast, the rates for tobramycin against the same isolates ranged from 9.5% to 39.9%, again with rates highest among the coagulase-negative strains. Rate for P. aeruginosa was 2.7% for both gentamicin and tobramycin.
Cephalosporins
Cephalosporins remain treatment options for treating bacterial conjunctivitis, keratitis, and endophthalmitis. In areas with high MRSA, MRSE, and MRCoNS rates, their use are limited. Nonsusceptibility among the cephalosporins (cefazolin, cefuroxime, and ceftazidime) is correlated with methicillin resistance. Isolates resistant to methicillin confer resistance to all beta lactams. [25, 35] The second-generation cephalosporins have varying activity against members of the Enterobacteriaceae and the streptococci and are ineffective against P. aeruginosa. [25] Ceftazidime susceptibility among Gram-negatives retains >95% for Gram-negative Enterobacteriaceae and P. aeruginosa in this study.
Vancomycin
Vancomycin susceptibility remains >95% for the most common Gram-positive ocular isolates with ranges from 99% to 100%. No true vancomycin-resistant S. aureus and/or S. epidermidis have been documented among ocular isolates in any of the surveillance studies in the United States. Reports of VRSA using disk diffusion are inappropriate and unreliable. Disk diffusion is not an acceptable method for detection of vancomycin intermediate and or resistant isolates.
Vancomycin-resistant enterococci have been recovered from cases of posttraumatic endophthalmitis. The majority of these have been Enterococcus faecalis and/or Enterococcus faecium associated with previous ocular surgery and immunosuppression. [36, 37] Hillier et al. describes a case of Enterococcus gallinarum following trauma. [38] Limitations of this study include its retrospective nature and current issues of patient sampling frequency, in vitro susceptibility testing and interpretation. Our center is a tertiary referral center and isolates and susceptibility profiles may reflect recovery of pathogens with a different pathology and susceptibility profile. The use of the Clinical Laboratory Standards Institute susceptibility breakpoints for serum and tissues may not accurately reflect the pharmacokinetics and pharmacodynamics of antibiotics in ocular tissues and fluids.
Spectrum and diversity of ocular pathogens along with their in vitro susceptibility patterns are influenced by climate, geographic region, patient populations, and prior antibiotic exposure. These factors may compromise extrapolation and application of these and similar surveillance data to other regions.
Conclusion
The spectrum and diversity of ocular pathogens have not changed significantly, over the last 10 years. What has changed is the declining rate of the in vitro efficacy of fluoroquinolone as coverage for the most common ocular pathogens, worldwide.
Fluoroquinolone monotherapy as standard therapy for common ocular infections should be reassessed. Ophthalmologists must become proactive and join the crusade to develop practical, prudent, and collaborative efforts in antibiotic stewardship for improved patient safety and optimal visual outcomes.
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